REGISTER
Intismeran Autogene Hits Phase III: A Milestone for Personalized mRNA Cancer Therapy
On 19 August 2026, Merck and Moderna announced that the Phase III INTerpath-001 trial of intismeran autogene plus pembrolizumab in resected Stage IIB-IV melanoma met both primary RFS and key secondary DMFS endpoints. The trial randomized 1,137 patients 2:1. Phase IIb KEYNOTE-942 had shown a 49% reduction in recurrence/death (HR 0.51) and 59% in distant metastasis/death (HR 0.411). Each vaccine encodes up to 34 neoantigens. INTerpath spans 9 Phase II/III trials. Phase III HR/CI pending.

mRNA technology reached a key clinical milestone in oncology on 19 August 2026. Merck and Moderna jointly announced that intismeran autogene—an individualized neoantigen therapy (INT)—combined with KEYTRUDA (pembrolizumab) for adjuvant treatment of patients with completely resected Stage IIB-IV melanoma met both its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase III INTerpath-001 trial.

According to the companies, this is the first Phase III positive top-line result for any individualized neoantigen therapy, and the first Phase III positive read-out for an mRNA cancer therapy.

Capital markets reacted quickly. On 19 August, during US trading, Moderna’s share price rose more than 150% intraday, while Merck climbed more than 10%.

The result has also refocused attention on Moderna’s oncology pipeline. As the COVID-19 vaccine business has entered a new phase, the company has continued to advance mRNA applications in oncology. For Merck, intismeran is one of several novel combination regimens built around KEYTRUDA.

Phase III: Two Key Endpoints Met Simultaneously

INTerpath-001 is a global, randomized, double-blind, placebo- and active-controlled Phase III clinical trial that enrolled 1,137 patients. Participants had completely resected cutaneous melanoma and had not received prior systemic therapy; eligible stages were high-risk IIB, IIC, III, or IV.

Patients were randomized 2:1 to receive intismeran autogene plus KEYTRUDA, or KEYTRUDA alone. Intismeran was administered every three weeks, up to nine doses; KEYTRUDA was administered every six weeks, up to nine cycles; total treatment duration was approximately one year.

In a pre-specified interim analysis, the combination met two key efficacy endpoints:

- Primary endpoint: recurrence-free survival (RFS).

- Key secondary endpoint: distant metastasis-free survival (DMFS).

The companies reported that, compared with KEYTRUDA alone, the intismeran plus KEYTRUDA combination achieved statistically significant and clinically meaningful improvements in RFS and DMFS. However, the announcement remains a top-line release: specific hazard ratios, confidence intervals, and data across disease stages and patient subgroups have not yet been disclosed. The study will continue follow-up and will further evaluate additional endpoints, including overall survival (OS). On safety, the companies reported that the combination’s profile was consistent with prior studies, with no new safety signals identified.

A Therapy “Tailored to Each Patient”

Intismeran autogene was previously designated V940, or mRNA-4157. Unlike conventional oncology drugs, intismeran uses an individualized neoantigen approach. After the patient’s tumor is resected, researchers analyze the tumor tissue to identify tumor-specific mutations and screen for potential neoantigens. A bespoke mRNA therapy is then designed based on the patient’s own tumor mutational profile, with each therapy containing synthetic mRNA encoding up to 34 neoantigens. After administration, these mRNA sequences enter cells and are translated into the corresponding antigens, which are presented to the immune system, inducing T-cell immune responses against these tumor-associated antigens.

In simple terms, the approach is to first analyze the patient’s own tumor, then design mRNA based on its mutational signature, helping the immune system recognize any residual tumor cells.

This represents one of the key distinctions between individualized neoantigen therapies and traditional “off-the-shelf” oncology drugs. The choice to combine intismeran with KEYTRUDA also follows a clear therapeutic logic. KEYTRUDA lifts the immune suppression imposed by the tumor’s PD-1 pathway, restoring effector T-cell anti-tumor immunity. Intismeran, by drawing on tumor-specific mutations, induces immune responses against those neoantigens. Together, intismeran helps the immune system recognize the tumor’s signature while KEYTRUDA further modulates the related immune response.

From Phase IIb to Phase III: Research Continues

The Phase III result is not intismeran’s first positive data point. At this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, Merck and Moderna reported the 5-year follow-up data from the KEYNOTE-942 / mRNA-4157-P201 study.

In patients with completely resected high-risk Stage III/IV melanoma, the intismeran plus KEYTRUDA combination reduced the risk of recurrence or death by 49% compared with KEYTRUDA alone (HR=0.51; 95% CI, 0.294-0.887) and reduced the risk of distant metastasis or death by 59% (HR=0.411; 95% CI, 0.200-0.843). The current INTerpath-001 result extends the signal to Phase III, meeting both the RFS primary endpoint and the DMFS key secondary endpoint.

Clinical development of intismeran has now expanded to additional tumor types. According to information from Merck and Moderna, the INTerpath program includes nine Phase II and Phase III clinical trials, covering melanoma, non-small cell lung cancer (NSCLC), bladder cancer, and renal cell carcinoma. The two companies are also conducting earlier-stage clinical studies in pancreatic ductal adenocarcinoma, gastric cancer, and NSCLC.

Looking ahead, INTerpath-001 will continue follow-up and evaluate additional endpoints, including OS. Merck and Moderna plan to present detailed study data at an upcoming international medical conference and to discuss submission plans with regulatory authorities.

Therefore, intismeran remains in clinical development and has not yet been approved for marketing. Subsequent milestones to watch include the full Phase III dataset, specific RFS and DMFS results, long-term follow-up including OS, and regulatory submission and review progress.

0
0
Loading